humacao_exterior

Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016

pharmafile | July 29, 2016 | News story | Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo 

Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps forward in key regulatory and clinical aspects of its Immuno-oncology pipeline.

The company reported a growth in its total revenues of 17% to 4$4.9 billion, alongside GAAP and non-GAAP Q2 earnings per share (EPS) of $0.69.

The firm is also celebrating the approval of Opdivo in the US for the treatment of classical Hodgkin lymphoma and in Europe for metastatic melanoma when combined as part of a regimen with Yervoy, in addition to  Empliciti’s approval in Europe for combination treatment of multiple myeloma.

“During the second quarter we delivered strong sales and earnings growth, achieved important regulatory milestones with Opdivo across multiple types of cancer, and further advanced our leadership in Immuno-Oncology through the breadth of the clinical data we presented at ASCO,” commented Giovanni Caforio, chief executive officer at BMS. “I am confident strong performance of our in-line products, progress with our diversified pipeline and our focused approach to business development position us well for continued success.”

Matt Fellows

Related Content

Elekta and BMS partner for digital treatment for melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

Latest content